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included. The index date was chosen such that each patient had
at least 6 month’s treatment with either of the products—before
and at least 6 months after that date. Patients receiving other
oral anti-diabetic drugs were excluded. To compensate for lack
of double-blind randomization and to reduce selection bias,
patients in the pioglitazone group were matched 1 :1 with the
insulin group based on propensity score calculated using demo-
graphic characteristics, co-morbidities, medical therapies, dura-
tion of diabetes, and duration of treatment. The odds ratio for
the microvascular event in the follow-up period was determined
using logistic regression with treatment as a factor and signiﬁ-
cant (p < 0.1) baseline characteristics as covariates in the model.
RESULTS: A total of 453 patients in the pioglitazone group were
matched to 453 patients in the insulin group. The crude event
rate in the pioglitazone group was 3.09% compared with 
9.49% in the insulin group (p < 0.001) and the odds ratio was
0.304 for pioglitazone (95% CI = 0.164, 0.564; p < 0.001). The
signiﬁcant risk reduction projected for the pioglitazone group
could not be completely explained by baseline laboratory 
measurements of lipids, serum creatinine, blood pressures, or
duration of diabetes. CONCLUSION: In this retrospective,
propensity-matched analysis in patients with type-2 diabetes, the
pioglitazone-treated group was associated with a signiﬁcantly
lower incidence of microvascular events than the insulin-treated
group.
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OBJECTIVE: To assess the incidence of liver failure in associa-
tion with anti-diabetic treatment using pioglitazone versus other
oral anti-diabetic medications. METHODS: The study was a ret-
rospective analysis of claims data from the PharMetrics Patient-
Centric Database that had over 1.12 million enrollees with type
2 diabetes. All patients ≥18 years of age with type 2 diabetes
who had initiated treatment with either a thiazolidinedione
(pioglitazone and rosiglitazone), sulfonylurea, or metformin
were identiﬁed and matched on the basis of propensity scores,
which served as a proxy for severity of disease. The primary
measure of interest was the incidence of liver failure or hepati-
tis post-index date. In addition to unadjusted comparisons, Cox
proportional hazards models were employed to estimate the risk
of developing liver failure or hepatitis. RESULTS: There was no
signiﬁcant difference in the 1-year and 2-year incidence rates of
liver failure or hepatitis (primary and secondary diagnosis)
between the pioglitazone monotherapy group and respective
comparator groups (pairs matched with rosiglitazone, n = 1847
(p > 0.808); with sulfonylurea, n = 1474 (p > 0.219); and with
metformin, n = 1137 (p > 0.284)). Cox proportional hazards
models controlling for age, pre-index total health care costs,
charlson comorbidity index, procedures and a hospitalization or
ER visit for pre-index hyperglycemia echoed these results.
Further, no primary or secondary diagnosis of liver failure was
reported in the pioglitazone group during the follow-up period.
CONCLUSION: Results of retrospective data analysis using the
PharMetrics cohort of patients with type 2 diabetes demonstrate
that there is no evidence of increased risk of liver failure or
hepatitis for patients initiating therapy on pioglitazone compared
to other oral anti-diabetic agents. Pioglitazone therapy was not
associated with an increased risk of liver failure at 2 years 
relative to other oral anti-diabetic therapies.
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OBJECTIVES: The project focuses on improving the drug use
process in the management of patients with chronic diseases,
especially diabetes. This HRSA funded program includes educa-
tion and training of pharmacists in ﬁve community health centers
about speciﬁc disease state therapies, monitoring, and manage-
ment. The study hypotheses are: 1) patients exposed to the inter-
vention will have improved medical and patient outcomes based
on changes in HbA1c, diabetes symptoms, LDL, blood pressure,
and health related quality-of-life, and 2) process measures con-
sistent with best practices will improve for patients exposed to
the intervention. METHODS: The project uses a prospective
design to determine whether exposure to the intervention over
two years leads to improved outcomes and processes of care.
Patients are the unit-of analysis and serve as their own controls.
Subjects include adults with Type 2 Diabetes Mellitus and
HbA1c >8mg/dL within a 3-month period of enrollment. Sub-
jects meeting the inclusion criteria are consecutively drawn from
a subset of clinic patients. Medical outcome data are collected
from medical and laboratory records, pharmacy records and
patient self-report. Study measures include clinical indicators,
quality-of-life, satisfaction and HEDIS diabetes-related process
measures. Outcomes and process data is collected at baseline and
every six months. RESULTS: Of the 142 patients enrolled in the
study, 137 are at the 6-month level and 104 are at the 12-month
level. The means at baseline for HbA1c, lipids and blood pres-
sure were 9.45, 122.54 (LDL), 136.63 (systolic) and 80.70 (dias-
tolic) while the six-month means were 8.53, 110.74, 135.16,
79.59 respectively. Wilcoxon Sign-Ranked test indicated signiﬁ-
cant differences in HbA1c and LDL mean values (p <= 0.000 &
p <= 0.10 respectively). However, the differences were non-
signiﬁcant for blood pressure values. CONCLUSIONS: The
baseline and 6 month values of these clinical markers indicate
an improvement in diabetes health outcomes for the patients
included in this initiative. Early ﬁndings support a positive
impact of pharmaceutical care on diabetes outcomes.
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OBJECTIVES: Even though guidelines suggest glycosylated
hemoglobin A1c (HbA1c) testing at least twice a year for dia-
betics and despite the correlation between long term glycemic
control and reductions in overall health care costs and service
utilization, studies have estimated that only 75% of diabetes
patients receive annual HbA1c screening. The purpose of this
study was to examine the relationship between participation in
a free HbA1c home-testing program and several individual-
speciﬁc variables, including age level, gender, income range and
disease severity. METHODS: Participants enrolling in the
CarePatterns® Disease Management Program for Diabetes from
January 1, 2003 through June 30, 2003 and who opted to par-
ticipate in the free home-based HbA1c testing program were
included in the study. Allowing sufﬁcient time for test comple-
tion and return, Chi-squared (c2) and Cochran-Mantel-Hanzel
(CMH) statistics were utilized to examine the relationship
between home-testing participation and the independent 
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variables. RESULTS: Of the 2624 home-testing participants, the
overall HbA1c test completion rate was 49.5%, with males sig-
niﬁcantly more likely to complete the test than females (52.3%
vs. 46.1%; c2: p = 0.001). Although home-testing participation
increased signiﬁcantly with age (c2: p < 0.0001), a signiﬁcantly
lower rate of participation was observed at the highest level of
disease severity (c2: p = 0.0006). No signiﬁcant relationship
between participation and income level existed. There was a sig-
niﬁcant interaction effect between age and gender, with the rela-
tionship between gender and home-testing participation
reversing as age increased (CMH: p < 0.0001). Gender also sig-
niﬁcantly mediated the impact of disease severity on participa-
tion (CMH: p = 0.001), with the impact of increased disease
severity occurring only for females (c2: p < 0.0001). CONCLU-
SIONS: This study suggests that signiﬁcant differences in
program responsiveness exist by demographic and condition-
speciﬁc variables. Strategies to effectively target these segments
of lower responsiveness will improve the viability and success of
a home-based A1c monitoring program.
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OBJECTIVE: The value of self-monitoring of blood glucose
(SMBG) by patients with type 2 diabetes is controversial. The
objective of this study is to examine the relationship between
SMBG and glycemic control among veterans who receive oral
hypoglycemic medications only for diabetes. METHODS:
Veterans with diabetes mellitus at a Texas Veterans Health care
System were selected by identifying those with an ICD-9 code
for diabetes from the outpatient ﬁle. Veterans who received con-
tinuous care at the VA from FY 2000 to 2002 were selected.
From this cohort, a sub cohort of veterans was identiﬁed who
received oral hypoglycemic medications only during all 3 years
of study period. The cohort was placed into 4 mutually exclu-
sive groups based on the duration of SMBG. These groups were
deﬁned as “did not receive monitoring strips at all”; “received
last year”; “received last 2 years”; and “received all 3 years”.
RESULTS: Of the 1185 veterans who received oral hypoglycemic
medications, 976 veterans met the criteria for one of the groups.
There were no signiﬁcant differences among the groups on base-
line Hba1c, BMI, casemix score. There were signiﬁcant differ-
ences in age and race. Pairwise comparison showed that mean
rank for age was older among those who did not receive strips
at all compared to those who received strips the last year (p <
0.0083). Results of robust regression showed that age and being
Hispanic (compared to white) were signiﬁcant predictors of
Hba1c at FY 2002 (controlling for baseline Hba1c). (F = 49.77
(9, 906 p < 0.001). Age was inversely related to Hba1c. Dura-
tion of monitoring (including not monitoring at all) was not a
signiﬁcant predictor of Hba1c at FY 2002. CONCLUSIONS:
The results suggest there were some signiﬁcant differences in age
and race among those who received monitoring supplies and
those who did not. Receiving strips and duration of receiving
strips were not signiﬁcantly associated with glycemic control.
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OBJECTIVES: Previous research has found that women with
diabetes are at a higher risk for cardiovascular disease mortality
than men with diabetes. The purpose of this study was to deter-
mine whether there were gender-related differences in the man-
agement of dyslipidemia in managed care enrollees with diabetes.
METHODS: Retrospective cross-sectional analyses were con-
ducted using medical and pharmacy claims data from a large
health maintenance organization across a two-year period
(2000-1). Patients with type-2 diabetes were identiﬁed through
a validated algorithm of medication and diagnosis codes. Bivari-
ate analyses were conducted with chi-square analysis to deter-
mine if women were less likely than men to receive a lipid test
or a lipid-modifying drug. Logistic regression models were also
constructed to compare gender-related differences while con-
trolling for age and illness severity. Prior hospitalization and the
intensity of diabetes drug therapy served as proxies for illness
severity. All statistical analyses were performed using SPSS,
version 11.0. RESULTS: A total of 2360 patients with type-2
diabetes were included in the analyses. Across 2000 and 2001,
79.4% of women received a lipid test as compared to 84.2% of
men (chi-square = 6.69, p = 0.01). Also, 33.2% of women
received a lipid-modifying drug as compared to 45.5% of men
(chi-square = 27.31, p < 0.001). Logistic regression analyses
revealed that men were more likely than women to receive a lipid
test when controlling for age, hospitalization in year 2000, and
intensity of diabetes drug therapy (OR = 1.42, CI = 1.09 to 1.84).
Men were also more likely than women to receive a lipid-
modifying drug when controlling for age, prior hospitalization,
diabetes drug intensity and lipid-testing (OR = 1.57, CI = 1.28
to 1.94). CONCLUSIONS: Women with type-2 diabetes were
less likely than men with type-2 diabetes to receive lipid tests or
lipid-modifying drugs.
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OBJECTIVES: To compare the risk of diabetes associated with
olanzapine, quetiapine, and risperidone in treating patients with
schizophrenia. METHODS: Schizophrenia patients taking
mono-atypical therapy were selected from North Carolina Med-
icaid Claims database from July 1998 through October 2000.
Patients were included if they were continuously eligible in the
North Carolina Medicaid program with no diagnosis of diabetes
during the three-month pre-treatment period. While controlling
for patient demographic and clinical characteristics, comorbidi-
ties, and medication use in the baseline period, multivariate logit
models were employed to compare the odds ratios for diabetes
associated with atypical antipsychotic treatments. RESULTS:
A total of 581 patients were included. Of these, 322 initiated
olanzapine, 44 initiated quetiapine, and 215 initiated risperi-
done. Mean age was 40.7 years, 54.7% were men and 46% were
whites. No statistically signiﬁcant differences were found in rates
of diabetes among the three cohorts, where the adjusted odds
ratio and 95% conﬁdence intervals were 1.39 (0.684–2.838) for
olanzapine vs. risperidone, 0.897 (0.255–3.155) for olanzapine
vs. quetiapine, and 0.973 (0.495–1.914) for quetiapine vs.
risperidone. Otherwise, all included factors being equal, a higher
risk of diabetes appeared to be associated with female and the
prior use of antidepressants. CONCLUSIONS: Based on the NC
Medicaid population, the risk of diabetes for patients with schiz-
ophrenia did not appear to differ across the treatment groups of
olanzapine, quetiapine, and risperidone.
